Verastem raises $100M, plots path forward with targeted cancer combo
The biotech will scale back some commercial operations for Copiktra as it tests a newly acquired pipeline asset
Based on an early peek at clinical data, an investor syndicate is endorsing Verastem’s strategic realignment behind a pipeline combo in a targeted cancer indication. The group is pouring $100 million into the company at a double-digit premium as the biotech pares expenses.
Verastem Oncology Inc. (NASDAQ:VSTM) has identified as a key